Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.0K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.0K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

772
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
772
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

650
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
650
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

916
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
916
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

917
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
917
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

712
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
712

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction notice to 'Propranolol to decrease time to delivery: a meta-analysis of randomized controlled trials'. Retraction notice to AJOGMF Volume 6, Issue 10/ October 2024/ 101459.

American journal of obstetrics & gynecology MFM·2026
Same author

Association of Prepregnancy Obesity and Excessive Gestational Weight Gain with Perinatal Outcomes among Patients with Pregestational Diabetes.

American journal of perinatology·2026
Same author

Identification of de novo variants from parent-proband duos via long-read sequencing.

American journal of human genetics·2026
Same author

Acute Fatty Liver of Pregnancy and Fetal Fatty Acid Oxidation Disorders: A Systematic Review.

O&G open·2026
Same author

Hereditary Anemias as a Monogenic Etiology for Nonimmune Hydrops Fetalis.

Clinical therapeutics·2026
Same author

First-Trimester Machine Learning to Predict Preeclampsia in Normotensive Pregnancies by American Heart Association Guidelines.

American journal of perinatology·2026

Related Experiment Video

Updated: Sep 20, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K

Propranolol to decrease time to delivery: a meta-analysis of randomized controlled trials.

Sonia Biswas1, Mariella Toro2, Rebecca Horgan3

  • 1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (Biswas, McLaren, Berghella, and Al-Kouatly).

American Journal of Obstetrics & Gynecology MFM
|May 25, 2025
PubMed
Summary
This summary is machine-generated.

Propranolol use during labor induction or augmentation did not significantly shorten the time to delivery. This meta-analysis found no increased risks of adverse outcomes with propranolol.

Keywords:
augmentationbeta-blockerinductionlaborpropranolol

More Related Videos

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.0K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.7K

Related Experiment Videos

Last Updated: Sep 20, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.0K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.7K

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Clinical Trials

Background:

  • Labor induction and augmentation are common obstetric interventions.
  • Identifying agents that can optimize labor duration is of clinical interest.

Purpose of the Study:

  • To assess the effect of propranolol on the time to delivery in patients undergoing labor induction or augmentation.
  • To evaluate the safety profile of propranolol in this context.

Main Methods:

  • A systematic search of multiple databases (PubMed, Scopus, Cochrane Library, ClinicalTrials.gov, CINAHL) was conducted up to December 2023.
  • Included were randomized controlled trials comparing propranolol with placebo or standard care for labor induction/augmentation.
  • The primary outcome was time to delivery; secondary outcomes included adverse events.

Main Results:

  • Five randomized controlled trials with 660 patients were included.
  • Propranolol did not significantly decrease the time to delivery in either labor induction or augmentation.
  • Pooled analysis showed no significant difference in time to delivery (mean difference: -4.33 minutes; 95% CI: -22.48 to 13.83).
  • No increased risk of postpartum hemorrhage, blood transfusion, cesarean delivery, or NICU admission was observed.

Conclusions:

  • Propranolol does not significantly reduce the time to delivery when used for labor induction or augmentation.
  • The use of propranolol in labor induction and augmentation appears safe, with no increased risk of major adverse outcomes.